UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of GBP 508.91 million. The enterprise value is 453.95 million.

Market Cap	508.91M
Enterprise Value	453.95M

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.11M
Shares Outstanding	n/a
Shares Change (YoY)	+40.86%
Shares Change (QoQ)	+0.83%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	34.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.16
PB Ratio	-14.15
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.24
EV / Sales	6.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.46

Financial Position

The company has a current ratio of 5.65

Current Ratio	5.65
Quick Ratio	5.13
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.18
Interest Coverage	-7.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-29.80%
Return on Invested Capital (ROIC)	-96.25%
Return on Capital Employed (ROCE)	-51.97%
Revenue Per Employee	303,877
Profits Per Employee	-457,881
Employee Count	235
Asset Turnover	0.41
Inventory Turnover	1.28

Taxes

In the past 12 months, UroGen Pharma has paid 2.45 million in taxes.

Income Tax	2.45M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-21.53%
50-Day Moving Average	9.01
200-Day Moving Average	11.16
Relative Strength Index (RSI)	77.72
Average Volume (20 Days)	45,505

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.48

Income Statement

In the last 12 months, UroGen Pharma had revenue of GBP 71.11 million and -107.14 million in losses. Loss per share was -2.36.

Revenue	71.11M
Gross Profit	63.77M
Operating Income	-82.71M
Pretax Income	-104.69M
Net Income	-107.14M
EBITDA	-82.49M
EBIT	-82.71M
Loss Per Share	-2.36

Full Income Statement

Balance Sheet

The company has 151.62 million in cash and 97.80 million in debt, giving a net cash position of 57.31 million.

Cash & Cash Equivalents	151.62M
Total Debt	97.80M
Net Cash	57.31M
Net Cash Per Share	n/a
Equity (Book Value)	-35.96M
Book Value Per Share	-0.78
Working Capital	151.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -82.86 million and capital expenditures -262,383, giving a free cash flow of -83.12 million.

Operating Cash Flow	-82.86M
Capital Expenditures	-262,383
Free Cash Flow	-83.12M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 89.68%, with operating and profit margins of -116.31% and -150.68%.

Gross Margin	89.68%
Operating Margin	-116.31%
Pretax Margin	-147.23%
Profit Margin	-150.68%
EBITDA Margin	-116.01%
EBIT Margin	-116.31%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.86%
Shareholder Yield	n/a
Earnings Yield	-21.05%
FCF Yield	-16.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -3.85 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.85
Piotroski F-Score	2